Natco Pharma shares jump 4% amid weak broader markets; here' why
Shares of Natco Pharma Ltd surged nearly 4.35 per cent to Rs 1,413.45 on Monday, commanding a total market capitalization close to Rs 25,000 crore.
Here's why Natco Pharma share price gained over 4% on October 7; details
Natco Pharma share rose after the company announced that Mylan Pharmaceuticals Inc & Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic (Semaglutide)
Natco Pharma shares rise 4% on settlement order in US patent case over generic Ozempic
The strong up move was seen in the stock price with the scrip touching the day's high of Rs 1,408.70 per share on the NSE, rising 4 percent.
Natco Pharma shares gain after settlement in US patent litigation on generic Ozempic
Mylan Pharmaceuticals Inc and Novo Nordisk, the original patent holder for Ozempic, have reached a settlement in the US patent litigation concerning the drug, Natco Pharma informed the stock exchanges in a filing.
Natco shares gain after antidiabetic drug partner Mylan, Novo Nordisk settle patent litigation
Natco Pharma shares rise 3% as partner Mylan settles U.S. patent litigation with Novo Nordisk for generic Ozempic.
Natco Pharma partner Mylan settles patent litigation with Novo Nordisk over generic Ozempic in US
Hyderabad: NATCO Pharma Limited has announced that its partner Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the U.S. patent litigation related to generic
Mylan settles patent litigation with Novo Nordisk over generic Ozempic in United States
According to a report by news agency PTI, NATCO and Mylan have partnered for the development of generic Ozempic (Semaglutide) products, the company said in a regulatory filing. Ozempic is a prescription medication patented by Novo Nordisk.
BioSpace3h
Novo, Viatris Settle Ozempic Patent Row
Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the ...
FiercePharma1d
Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case
With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...
The Pharma Letter7h
Novo Nordisk settles patent lawsuit over Ozempic
Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US ...
L&T, Cochin Shipyard and 3 more: Axis Direct recommends buying these stocks for 5-15 days | Check targets, stop losses
Ahead of the market opening on Wednesday, Axis Direct picked five stocks that can generate profits in 5 to 15 days. These are ...
Stock market update: Nifty Pharma index advances 0.65% in an upbeat market
Gland Pharma Ltd.(down 0.36 per cent) and Natco Pharma Ltd.(down 0.24 per cent) were the top losers on the index. The Nifty ...